A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma

• DOI: 10.18632/aging.202446
• Publication Date: 2021-01-20T20:08:01Z
• Authors: Xiaozai Xie; Yi Wang; Sina Zhang; Jialiang Li; Zhengping Yu; Xiwei Ding; Longyun Ye; Peirong Gong; Qiandong Zhu; Junjian Li; Ziyan Chen; Xinfei Yao; Zhiyong Du; Qiqiang Zeng; Hanbin Chen; Zhen Yang; Gang Chen
• Keywords: Signature (topology)

Cholangiocarcinoma (CCA) is a fatal disease with dismal survival rates. Long non-coding RNA (lncRNA) expression profiling as potential prognostic biomarkers play critical roles in tumor initiation, development, and poor prognosis. Identifying specific lncRNA to predict the prognosis of CCA patients early stages very important for improving patient's survival. In current study, we aimed establish novel risk-stratification signature panel CCA. The initial discovery was identified Cancer Genome Atlas database (TCGA cohort). Cox regression analysis used model receiver operating characteristic (ROC) curve performed assess specificity sensitivity model. This followed by independent validation from First Affiliated Hospital Wenzhou Medical University (WMU Furthermore, using Gene Ontology function Kyoto Encyclopedia pathway enrichment analysis, explored lncRNA. Finally, five (HULC; AL359715.5; AC006504.8; AC090114.2; AP00943.4) were screened predictive that significantly associated overall survival(HR:4.879;95%CI,1.587-14.996;p=0.006). five-lncRNA showed excellent accuracy TCGA cohort (AUC=0.938), also robustly predicted WMU cohort(AUC=0.816). Functional suggested primarily CCA-related biological processes. Our data established robust identification molecular genotypes. Moreover, it revealed new mechanisms